The team at Bell Potter has identified an ASX 200 share that they believe could generate big returns for investors.

And while no dividend is expected in 2026, it could pay to be patient, with the broker expecting a big dividend yield next year.

Which ASX 200 share?

The share that has caught the eye of Bell Potter is Nickel Industries Ltd (ASX: NIC).

It notes that the nickel producer has announced deals to acquire more production capacity. It said:

NIC has announced it will acquire interests in expansions to the existing ENC HPAL facility (46% NIC) which will lift its attributable nickel in HPAL capacity by ~17ktpa (41%) to 58.6ktpa. NIC will acquire a 17.5% interest in the 36ktpa PT Teluk Metal Industry (TMI) expansion for US$169m cash consideration. Separately, NIC will acquire a 36% interest in the 28ktpa PT Chengsheng New Energy (CNE) expansion via an equity swap with consideration being an 18% interest in the Sampala Project (reducing NIC from 60% to 42%). TMI and CNE are both expected to come online in mid-2027 with ore supply from Sampala.

The TMI acquisition is subject to a Construction Guarantee capping the acquisition cost at US$169m and delivery of nameplate production by September 2027. NIC expects to fund the cash payment, due 26 November 2026, from existing cash and operating cash flow. If needed, NIC’s major shareholder (Shanghai Decent) will provide debt funding on commercial terms. NIC held cash and equivalents of US$212m at end March 2026.

Big potential returns

According to the note, Bell Potter has retained its buy rating on the ASX 200 share with an improved price target of $1.55 (from $1.45).

Based on its current share price of 89 cents, this implies potential upside of almost 75% for investors over the next 12 months.

And as mentioned at the top, no dividend is expected in FY 2026. However, in FY 2027 an unfranked 6 cents per share dividend is forecast, followed by a 14 cents per share dividend in FY 2028.

This implies potential dividend yields of 6.75% and 15.7%, respectively.

Commenting on its buy recommendation, Bell Potter said:

EPS changes in this report are: CY26: +1%, CY27 +5%, CY28 +16%. NIC offers nickel price leverage and diversified margin exposure across an integrated value chain. The HPAL expansion transactions will further balance NIC’s earnings into downstream higher-margin operations and preserve earnings through the nickel price cycle. We lift our Target Price 7% to $1.55/sh and retain our Buy rating.

The post Should you buy this ASX 200 share for its 15% forecast dividend yield? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• This ASX 200 stock is up almost 30% in a year. Now it is making another big move
• Nickel Industries shares: US$169m TMI HPAL investment boost
• This ASX 200 mining stock is up 44% in a year. Why is it climbing again?
• Why AIC Mines, EOS, Flight Centre, and Nickel Industries shares are racing higher today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

EchoIQ Ltd (ASX: EIQ) shares were on fire on Friday.

The ASX tech stock rocketed 30% to $1.62 after Pro Medicus Ltd (ASX: PME) announced a major investment in the company and a marketing agreement.

The market appears to see this investment as a stamp of approval from the medical imaging technology provider.

Pro Medicus’ CEO, Dr Sam Hupert, commented:

In addition to providing financial backing, we are looking to offer our Visage 7 Cardiology customers the option of Echo IQ’s technology. This is in line with our AI strategy of offering a curated suite of algorithms that will be a mixture of algorithms created by us, those created in conjunction with our clinical partners and 3rd party algorithms such as Echo-IQ.

Is it too late to buy this ASX tech stock?

The good news is that Bell Potter doesn’t believe it is too late to buy this high-flying share. However, the near-term upside from here could be limited.

According to a note, the broker has initiated coverage on the cardiology-focused medical technology company’s shares with a speculative buy rating and $1.65 price target. This is just a fraction higher than where its shares currently trade.

Bell Potter believes there is a major unmet need that the ASX tech stock could help with. It explains:

The major unmet need in this patient population are those currently asymptomatic (i.e. without obvious symptoms) with severe disease. The vast majority proceed to symptomatic disease within two years and become candidates for aortic value replacement. Recent clinical data has proven that early intervention drives a significant survival benefit.

The data suggest that the majority of these patients are not identified using current screening methods and fewer still receive treatment. Finally, this recent clinical data has been recognised by CMS which recently proposed an update to its National Coverage Determination to extend reimbursement for AS patients with asymptomatic disease.

Commenting on its speculative buy rating, Bell Potter adds:

We commence coverage with a Buy (Speculative) recommendation and valuation of $1.65. We expect EIQ expand rapidly over the short to medium term as healthcare operators and payers recognise the benefit of these diagnostic aides in helping to minimise the long term cost of heart failure to US healthcare.

Overall, this could make it one to watch in the near term.

The post Is this exciting ASX tech stock a buy after its massive news? appeared first on The Motley Fool Australia.

More reading

• Pro Medicus just struck a revolutionary AI cardiology deal. Here’s why that matters
• Why is everyone talking about Mineral Resources, A2 Milk and Pro Medicus shares on Thursday?
• Why A2 Milk, EchoIQ, Lendlease, and Qantas shares are racing higher today
• A deal with Pro Medicus has turned this ASX biotech into a 10-bagger, up more than 30% today
• Pro Medicus shares jump again as AI deal adds fuel to 40% rally

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Investing can be a time-consuming activity. There are individual shares to research, broker notes to read, earnings results to follow, market moves to interpret, and endless opinions about what will happen next.

ASX exchange traded funds (ETFs) can help cut through some of that noise.

They allow investors to spread money across a basket of companies in one trade, which can make portfolio building much simpler and removes the need to pick individual stocks.

But which ASX ETFs could make buy and hold investing easy? Here are three to look closer at:

Vanguard MSCI Index International Shares ETF (ASX: VGS)

The first ASX ETF to look at is the Vanguard MSCI Index International Shares ETF.

This fund gives investors broad exposure to developed share markets outside Australia.

That is important because the Australian market is relatively small and heavily tilted toward banks and miners.

The Vanguard MSCI Index International Shares ETF opens the portfolio to companies listed in markets such as the United States, Europe, Japan, and other developed economies.

It can give investors exposure to global technology leaders, healthcare giants, consumer brands, industrial businesses, and financial companies that are simply not available in the same depth on the local market.

It gives investors a way to reduce home bias, access global growth, and avoid relying too heavily on the fortunes of the Australian economy alone.

Betashares Australian Quality ETF (ASX: AQLT)

But if you do want some exposure to the local market, then it could be worth looking at the Betashares Australian Quality ETF.

This fund gives investors exposure to Australian companies that pass a quality screen.

That makes it quite different from simply buying the largest companies on the ASX. Instead of letting size alone determine the portfolio, the fund looks for businesses with stronger financial characteristics.

This can include companies with more attractive profitability, healthier balance sheets, and better earnings quality. That type of filter can be useful in the Australian market.

VanEck Morningstar Wide Moat ETF (ASX: MOAT)

A third ASX ETF to consider is the VanEck Morningstar Wide Moat ETF.

This fund is built around the idea that some companies have stronger defences than others.

In investing terms, a moat is what helps a business protect its profits from competitors. It might come from a powerful brand, cost advantage, network effect, valuable intellectual property, customer loyalty, or a product that is difficult to replace.

The VanEck Morningstar Wide Moat ETF applies that idea to US shares, looking for stock with lasting competitive advantages and fair valuations.

That second part is important because even great businesses can disappoint investors if they are bought at the wrong price.

For long-term investors, this ASX ETF can add a more selective style of US exposure. It is a way to own a portfolio of companies chosen for business strength rather than simply market size.

The post 3 excellent ASX ETFs for easy buy and hold investing appeared first on The Motley Fool Australia.

More reading

• Which ASX ETFs are good options for a $1,000 investment?
• How I’d invest $250 a week in ASX shares to aim for $700,000
• 10 amazing ASX ETFs for the next decade
• Invest like Warren Buffett with these top ASX ETFs
• 5 high-quality ASX ETFs to buy with $5,000

Motley Fool contributor James Mickleboro has positions in VanEck Morningstar Wide Moat ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended VanEck Morningstar Wide Moat ETF and Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.